跳至主要内容
临床试验/EUCTR2007-001855-20-NL
EUCTR2007-001855-20-NL进行中(未招募)不适用

A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention deficit hyperactivity disorder - Effects of atomoxetine on attention and driving in adult ADHD

Faculty of Social Sciences, Utrecht University0 个研究点目标入组 30 人开始时间: 2008年6月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Adult men and women diagnosed with ADHD
  • -Possession of a valid driver's license for at least 3 years
  • -For women of childbearing potential, a negative urine beta-HCG pregnancy test result at test days
  • -Normal static binocular acuity, corrected or uncorrected
  • -Normal hearing
  • -Be considered as reliable and mentally capable of adhering to the protocol
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Depression or anxiety disorder, unless controlled and stable with medication
  • -Current drug use (positive urine drug screen on the presence of amphetamines (including MDMA), barbiturates, benzodiazepines, cocaine, and opiates)
  • -Use of psychoactive medication
  • -Positive alcohol breath test
  • -Prior enrolment in the same study
  • -Participation in another clinical trial

研究者

发起方
Faculty of Social Sciences, Utrecht University

相似试验

撤回
不适用
A double blind placebo-controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention-deficit hyperactivity disorderADHD10009841Attention Deficit Hyperactivity Disorder
NL-OMON31557niversiteit Utrecht30
已完成
2 期
The use of APL510 to improve the length of day time sleep in subjects working permanent night-shiftsMental and Behavioural DisordersNonorganic sleep disordersInsomnia
ISRCTN15733268Alliance Pharmaceuticals Ltd (UK)44
已完成
2 期
1.5 versus 3.0 mg APL510 to normalise sleep patterns in elderly subjects with insomniaMental and Behavioural DisordersNonorganic sleep disordersInsomnia
ISRCTN82088636Alliance Pharmaceuticals Ltd (UK)80
进行中(未招募)
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/A
EUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80
进行中(未招募)
1 期
A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night shifts.Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)
EUCTR2005-000120-17-GBAlliance Pharmaceuticals Ltd60